+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain



RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain



Human Mutation 22(4): 337



Germ-line mutations in the breast cancer susceptibility genes BRCA1 and BRCA2 account for a large proportion of hereditary breast/ovarian cancer families. A large number of disease-causing germ-line mutations and variants of unknown pathological significance have been identified in both genes. The majority of these variants have been studied only in genomic DNA and their effects at the mRNA level have not been reported. Our aim was to ascertain the pathological effect of six BRCA1 and two BRCA2 sequence unclassified variants by RNA analysis. Three of the BRCA1 variants are novel: IVS18+5G>A, IVS20-6_IVS20-4del and IVS22-2A>G. Three BRCA1 mutations showed aberrant splicing: Ala1693del, IVS18+5G>A and IVS22-2A>G. The variants G1706A, S1715N and IVS20-6_IVS20-4del in BRCA1, and T2515I and IVS25+9A>C in BRCA2 led to normal transcripts. We compared these RNA results with those obtained from two theoretical splicing prediction methods. The consensus values for the splice sequences (Shapiro and Senapathy 1987) involved in three of the BRCA1 splicing site variants agreed with the RNA results, lending support to the validity of this model. Moreover, we used previously established exonic splicing enhancer (ESE) sequences to ascertain whether the four exonic variants studied fell within predicted ESE motifs and whether they would disrupt ESE functions. Our results suggest that the splicing predictions based on this method are not definitive and should be considered with caution. This work highlights the importance of studying mutations at DNA and RNA levels in order to clarify their pathological effect. This information is essential for providing efficient counseling for breast/ovarian cancer families.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 050096694

Download citation: RISBibTeXText

PMID: 12955719

DOI: 10.1002/humu.9176


Related references

Pathogenicity evaluation of BRCA1 and BRCA2 unclassified variants identified in Portuguese breast/ovarian cancer families. Journal of Molecular Diagnostics 16(3): 324-334, 2014

Molecular study of the BRCA1 and BRCA2 genes in 153 breast cancer families from Castilla and León (Spain): new nine unclassified variants identified. Medicina Clinica 119(12): 441-445, 2002

BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families. Disease Markers 32(6): 343-353, 2012

BRCA1 and BRCA2 germline mutations in Uruguayan breast and breast-ovarian cancer families. Identification of novel mutations and unclassified variants. Breast Cancer Research and Treatment 128(1): 211-218, 2011

BRCA1 and BRCA2 germline mutations in Moroccan breast/ovarian cancer families: novel mutations and unclassified variants. Gynecologic Oncology 125(3): 687-692, 2012

Genetic analysis of BRCA1 and BRCA2 in breast/ovarian cancer families from Aragon (Spain): two novel truncating mutations and a large genomic deletion in BRCA1. Breast Cancer Research and Treatment 112(2): 353-358, 2008

Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer. Bmc Cancer 16: 64, 2016

Mutational analysis of BRCA1 and BRCA2 in hereditary breast and ovarian cancer families from Asturias (Northern Spain). Bmc Cancer 13: 243, 2013

Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases. Nucleic Acids Research 40(Database Issue): D992, 2012

Screening of 1331 Danish breast and/or ovarian cancer families identified 40 novel BRCA1 and BRCA2 mutations. Familial Cancer 10(2): 207-212, 2011

Sequence Variants of BRCA1 and BRCA2 Genes in Four Iranian Families with Breast and Ovarian Cancer. Iranian Journal of Public Health 40(2): 57-66, 2011

Unclassified Variants of BRCA1 and BRCA2 in Korean Patients With Ovarian Cancer. International Journal of Gynecological Cancer 28(2): 308-315, 2018

Molecular characterization and cancer risk associated with BRCA1 and BRCA2 splice site variants identified in multiple-case breast cancer families. Human Mutation 26(5): 495, 2005

Molecular Characterization and Cancer Risk Associated with BRCA1 and BRCA2 Splice Site Variants Identified in Multiple-Case Breast Cancer Families. Human Mutation 35(4): 511-511, 2014

Twenty-three novel BRCA1 and BRCA2 sequence variations identified in a cohort of Swiss breast and ovarian cancer families. Cancer Genetics and Cytogenetics 169(1): 62-68, 2006